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ABSTRACT
Objective: To evaluate the long-term effectiveness and
tolerability of adalimumab in the treatment of psoriatic
arthritis (PsA).
Methods: Patients with PsA who completed a 24-week,
double-blind study of adalimumab versus placebo were
eligible to enroll in an open-label extension study and
receive adalimumab 40 mg subcutaneously every other
week for up to an additional 120 weeks. At the time of
this analysis, available efficacy evaluations throughout
2 years of treatment (n = 245) included American
College of Rheumatology (ACR) 20%, 50% and 70%
improvement scores, measures of joint disease and skin
disease, disability and quality of life; modified total Sharp
scores (mTSS) were available for 2.75 years of treatment for
patients who received adalimumab in the 24-week study.
Results: After 24 weeks of double-blind treatment, the
mean change in mTSS was 20.2 for the adalimumab
group (N = 144) and 1.0 for the placebo group
(N = 152; p,0.001), and outcomes for all individual
ACR component variables were significantly improved in
adalimumab compared with placebo-treated patients.
Compared with 24-week responses, inhibition of radio-
graphic progression and improvements in joint disease
were maintained in most patients during long-term, open-
label adalimumab treatment. Also, improvements in skin
disease were maintained, with .20% of patients
achieving the strict criterion of psoriasis area and severity
index 100. The nature and frequency of adverse events
during long-term adalimumab treatment were consistent
with the safety profile during short-term treatment.
Conclusions: The clinical and radiographic efficacy of
adalimumab demonstrated during short-term treatment
was sustained during long-term treatment. Adalimumab
has a favourable risk–benefit profile in patients with PsA.
Trial registration number: NCT00195689.
Psoriatic arthritis (PsA) is an inflammatory arthri-
tis that occurs in up to one-third of patients with
psoriasis and is usually diagnosed years after the
skin disease appears.
12More than 50% of patients
with PsA experience progressive, erosive arthritis
that is often accompanied by functional impair-
ment.
3–6 Patients with psoriasis and PsA suffer
functional impairments that are associated with
direct healthcare costs (nearly US$650 million/
year), impaired health-related quality of life and
substantial work-related disability, including a
lower rate of employment.
1 2 7–10
Treatment for moderate to severe PsA tradition-
ally has included the same disease-modifying
antirheumatic drugs (DMARD) used for rheumatoid
arthritis (RA) (eg, methotrexate, leflunomide,
azathioprine, gold and sulfasalazine), despite
there being relatively little evidence for the
efficacy of these drugs in PsA and essentially no
evidence that they slow joint destruction in
PsA.
11–16 In fact, the number of joints affected
and the extent of joint damage frequently
increase in patients with PsA despite treatment
with salicylates, DMARD or glucocorticoids.
5 17–20
Adalimumab is a fully human, anti-tumour
necrosis factor (TNF) monoclonal antibody that
has been shown to have efficacy, alone or in
combination with methotrexate, in the treatment
of moderate to severe RA.
21–23 The Adalimumab
Effectiveness in Psoriatic Arthritis Trial (ADEPT)
demonstrated that, in patients with PsA, adalimu-
mab significantly improved skin and joint mani-
festations, lessened disability caused by joint
damage, inhibited structural changes on radio-
graphs and improved health-related quality of life
(HRQOL) while being generally well tolerated
during 24 weeks of therapy.
24 25 Patients who
completed the 24-week ADEPT study were eligible
to enroll in a 120-week open-label extension to
evaluate the long-term efficacy and safety of
adalimumab. The 48-week results of the open-
label extension demonstrated that adalimumab
improved joint and skin manifestations, reduced
disability and inhibited radiographic progression
during long-term treatment of patients with PsA.
25
Here we report the clinical efficacy and safety of
adalimumab for 2 years of treatment and the
radiographic efficacy for 2.75 years of treatment.
METHODS
Patients and protocol
Patients who completed the original 24-week
double-blind ADEPT study (N = 289) were eligi-
ble for this open-label extension study and 285
patients elected to enroll. Patients continued to
receive adalimumab 40 mg subcutaneously every
other week for up to 144 weeks of total adalimu-
mab exposure. The first adalimumab exposure
occurred at the start of the double-blind lead-in
study for patients randomly assigned to receive
adalimumab in ADEPT and at the start of the
open-label extension study for patients randomly
assigned to receive placebo in ADEPT. Patients
who received placebo during the lead-in study thus
had a duration of adalimumab exposure that was
24 weeks less than patients who received adalimu-
mab during the lead-in study. After 12 weeks in
the extension study, patients who did not have a
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tender joint count and the swollen joint count were allowed to
increase the adalimumab dosage to 40 mg a week. Non-steroidal
anti-inflammatory drugs (NSAID), prednisone, and/or DMARD
could not be initiated during the extension study but were
continued for patients who were receiving these medications at
the start of the extension study; tapering of any concomitant
medications for the treatment of PsA was allowed after 6 weeks
of treatment.
Descriptions of the clinical efficacy, radiographic efficacy and
safety assessments during the open-label extension study were
published previously,
25 as were HRQOL measures.
26
Statistical analyses
For all analyses, the efficacy and safety populations comprise all
patients (N = 298) who received any dosage of adalimumab in
the double-blind portion of ADEPT or in the open-label
extension study. Clinical efficacy and safety measures at all
time points were analysed and are reported based on the
duration of adalimumab exposure, with the exception of
radiographic data, which was analysed and is reported from
the baseline of ADEPT. For radiographic data, results were
analysed and are reported for 144 weeks (,2.75 years) of
adalimumab exposure. For patients without a week 144
modified total Sharp score (mTSS), the week 96 mTSS was
used to impute the week 144 score. For all other data (eg, clinical
assessments of joint and skin disease, HRQOL assessments),
results are reported for 104 weeks (2 years) of adalimumab
exposure based on available data at the time of this analysis.
Only patients with at least 3% body surface area involvement
at enrollment in ADEPT were included in the analyses of
psoriasis area and severity index (PASI) and dermatology life
quality index (DLQI). All data are last observation carried
forward (LOCF) unless otherwise noted. For patients whose
Table 1 Summary of changes in modified total Sharp score from baseline of the ADEPT to week 144 of
adalimumab treatment*
Change in mTSS{
Placebo/adalimumab{
N (%)
Adalimumab
N (%) 95% CI1
Baseline to week 24, N 128 115
Decrease/no change 90 (70.3) 103 (89.6) 82.5 to 94.5
Increase 38 (29.7) 12 (10.4) 5.5 to 17.5
Baseline to week 48, N 128 115
Decrease/no change 94 (73.4) 102 (88.7) 81.4 to 93.8
Increase 34 (26.6) 13 (11.3) 6.2 to 18.6
Week 24 to week 48, N 128 115
Decrease/no change 105 (82.0) 99 (86.1) 78.4 to 91.8
Increase 23 (18.0) 16 (13.9) 8.2 to 21.6
Baseline to week 144, N 128 115
Decrease/no change 88 (68.8) 91 (79.1) 70.6 to 86.1
Increase 40 (31.3) 24 (20.9) 13.9 to 29.4
Week 24 to week 144, N 128 115
Decrease/no change 99 (77.3) 89 (77.4) 68.7 to 84.7
Increase 29 (22.7) 26 (22.6) 15.3 to 31.3
Week 48 to week 144, N 128 115
Decrease/no change 104 (81.3) 92 (80.0) 71.5 to 86.9
Increase 24 (18.8) 23 (20.0) 13.1 to 28.5
Decrease is ,20.5 change; no change was 20.5 to 0.5 change; increase was .0.5 change.
*Patients included in this analysis are those who had a radiographic measure at baseline, week 24, week 48 and at week 96 or
week 144. Data are imputed; for patients who did not have a week 144 modified total Sharp score (mTSS), the week 96 mTSS was
used.
{Data are imputed; for patients who did not have a week 144 mTSS, the week 96 mTSS was used.
{Patients who were randomly assigned to receive placebo during the double-blind phase of the study began receiving open-label
adalimumab 40 mg every other week starting at week 24.
1An exact 95% CI was constructed based on the binomial distribution for the adalimumab group.
ADEPT, Adalimumab Effectiveness in Psoriatic Arthritis Trial.
Table 2 Mean changes in modified total Sharp scores in 144 weeks*
All
adalimumab
Adalimumab
non-progressors{
Adalimumab
progressors{
All placebo/
adalimumab{
Placebo/
adalimumab{
non-progressors{
Placebo/
adalimumab{
progressors{
N 115 103 12 128 90 38
Baseline mTSS, mean 22.3 16.1 74.9 21.9 14.9 38.5
Changes in mTSS, mean (SD)
Baseline to week 24 20.1 (1.20) 20.3 (0.93) 1.7 (1.62) 0.8 (2.42) 20.1 (0.51) 3.0 (3.56)
Baseline to week 48 0.1 (1.95) 20.3 (0.90) 2.9 (4.73) 0.8 (4.23) 20.3 (2.73) 3.3 (5.85)
Baseline to week 144 0.5 (4.20) 20.1 (1.75) 6.2 (10.77) 0.9 (6.36) 0.1 (1.72) 2.9 (11.23)
Week 24 to week 144 0.6 (3.62) 0.2 (1.88) 4.4 (9.26) 0.1 (5.71) 0.2 (1.72) 20.1 (10.23)
*Patients included in this analysis are those who had a radiographic measure at baseline, week 24, week 48 and at week 96 or week 144. Data are imputed; for patients who did not
have a week 144 modified total Sharp score (mTSS), the week 96 mTSS was used.
{Progression was defined as a mean change in mTSS .0.5 from baseline to week 24.
{Patients who were randomly assigned to receive placebo during the double-blind phase of the study began receiving open-label adalimumab 40 mg every other week starting at
week 24.
Extended report
Ann Rheum Dis 2009;68:702–709. doi:10.1136/ard.2008.092767 703adalimumab dosage was increased from 40 mg every other week
to 40 mg a week, the last observation before dosage increase
was carried forward when analysing American College of
Rheumatology (ACR) 20%, 50% and 70% improvement score
responses; PASI 50, PASI 75, PASI 90 and PASI 100 responses;
psoriatic arthritis response criteria (PsARC) and the physician’s
global assessment of psoriasis.
RESULTS
Study population
The baseline characteristics of patients who continued adali-
mumab treatment in the open-label extension study were
similar to those of the 313 patients who enrolled in ADEPT.
24 In
ADEPT, the overall population of treated patients (151 in the
adalimumab group and 162 in the placebo group) had mean
(SD) baseline scores of 25 (SD 18) for tender joint count, 14 (SD
12) for swollen joint count, 1.0 (SD 6) for health assessment
questionnaire disability index (HAQ DI) and 20.8 (SD 40.9) for
mTSS. These values are consistent with long-standing moderate
to severe PsA.
24 During the open-label extension period, 44
patients discontinued adalimumab treatment. The primary
reasons for discontinuation were adverse event (n = 10),
unsatisfactory therapeutic effect (n = 12), withdrawal of
consent (n = 8), death (n = 3), loss to follow-up (n = 1)
and other (n = 10).
Adalimumab exposure
The mean duration of treatment for the 298 patients who
received at least one dose of adalimumab was 699 days
(approximately 100 weeks) (median 785 days; range 26–785).
The adalimumab dosage was increased to 40 mg every week for
54 (18.9%) patients. The mean duration of adalimumab
treatment for these 54 patients was 542 days (approximately
77 weeks) (median 640 days; range 21–777). At week 12, the
first time point in the open-label extension study when a dosage
increase was allowed, 38 patients changed to a dosage regimen
of adalimumab 40 mg a week; the adalimumab dosage was
increased for the remaining 16 patients at one of the regularly
scheduled clinic visits that occurred at 12-week intervals
between week 24 and week 76 or at week 92.
Radiographic efficacy
The 24-week, double-blind portion of ADEPT demonstrated
that, compared with placebo, adalimumab significantly inhib-
ited structural deterioration of joints as seen on radiographs.
The mean change in mTSS was 20.2 for the adalimumab group
(N = 144) and 1.0 for the placebo group (N = 152;
p,0.001).
24 At week 24, 91.0% of adalimumab-treated patients
had no radiographic progression (mTSS change (0.5) compared
with 71.1% of placebo-treated patients.
24 At 48 weeks
(24 weeks into the open-label extension study), adalimumab
continued to inhibit structural damage in those patients who
had received adalimumab during the first 24 weeks of ADEPT
(mTSS mean change 20.1 at week 24 and 0.1 at week 48,
n = 133).
25 The mean changes in mTSS for patients who
received placebo for 24 weeks followed by adalimumab for
24 weeks (N = 141) were 0.9 at week 24 and 1.0 at week 48.
25
Table 1 demonstrates the percentage of patients with a
decrease (,20.5 units) or no change (,20.5 to 0.5 units of
change) or an increase (.0.5 units of change) in the mTSS over
different study periods, from baseline of ADEPT to week 144.
This analysis set included all patients who had a week-48 and a
week-96 or week-144 radiographic assessment (placebo/adali-
mumab, N = 128; adalimumab, N = 115). To week 24, 70.3%
(90/128) of patients receiving placebo demonstrated no progres-
sion compared with 89.6% (103/115) of adalimumab-treated
patients. Of the 115 adalimumab-treated patients, 88.7%
(n = 102) had a decrease/no change in mTSS to week 48 and
79.1% (n = 91) had a decrease/no change in mTSS to week
144. After week 24 of ADEPT, all patients originally randomly
assigned to receive placebo were switched to open-label
Figure 1 Percentages of patients achieving American College of
Rheumatology (ACR) 20%, 50% and 70% improvement score response
status to week 104 based on the duration of exposure to adalimumab
(including those patients originally randomly assigned to placebo). Data
are last observation carried forward. For patients who had an
adalimumab dosage increase, the last observation before the dosage
increase was carried forward. N = 281 at all time points to week 104.
Patients originally randomly assigned to receive placebo had a rapid
response when switched to adalimumab at week 24.
25
Figure 2 Percentages of patients achieving psoriasis area and severity
index (PASI) 50, PASI 75, PASI 90 and PASI 100 response status to
week 104 based on the duration of exposure to adalimumab (including
those patients originally randomly assigned to placebo). PASI was
assessed only for patients with at least 3% body surface area
involvement at enrollment. Data are last observation carried forward. For
patients who had an adalimumab dosage increase, the last observation
before the dosage increase was carried forward. N = 128 at all time
points to week 104.
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patients (N = 128) with no progression from weeks 24 to 144
was 77.3% (99/128); this percentage was similar to the 79.1%
(91/115) of patients originally randomly assigned to receive
adalimumab who had a decrease/no change in mTSS from
baseline to week 144. These results demonstrate the benefit of
adalimumab treatment in inhibiting structural joint damage.
To demonstrate further the maintenance of radiographic
inhibition, patients who were originally randomly assigned to
receive adalimumab in ADEPT who had no progression from
baseline to week 48 were evaluated at week 144 to determine
the percentage of patients with sustained inhibition of radio-
graphic progression as defined by a decrease/no change in the
mTSS. Of the 102 patients who had no progression from
baseline to week 48, 86 (84.3%) continued to demonstrate no
radiographic progression at week 144. The effectiveness of
adalimumab in inhibiting radiographic joint deterioration was
thus maintained for a large majority of patients throughout
144 weeks of adalimumab treatment.
For the same radiographic analysis set (adalimumab/placebo,
N = 128; adalimumab, N = 115), mean changes in mTSS are
shown in table 2. From baseline to week 24 of ADEPT, the mean
change in mTSS was 20.1 (SD 1.2) in adalimumab-treated
patients (N = 115) compared with 0.8 (SD 2.42) in placebo-
treated patients (N = 128). Once patients initially treated with
placebo began receiving adalimumab, the mean changes in
mTSS were similar in the placebo/adalimumab and adalimumab
treatment groups (0.0 (SD 3.03) and 0.2 (SD 1.43), respectively)
from weeks 24 to 48.
From week 48 to week 144, the mean changes in mTSS for
the placebo/adalimumab (N = 128) and adalimumab
(N = 115) groups were 0.1 (SD 5.24) and 0.4 (SD 2.61),
respectively. These differences in mean changes in mTSS from
week 48 to week 144 in the two treatment groups suggest that
patients treated continuously with adalimumab had less
progression of joint damage compared with patients who
switched from placebo to adalimumab treatment after week
24. To explore this unexpected finding further, additional
analyses were completed to investigate the mean changes in
mTSS over time for patients with and without radiographic
progression from baseline to week 24 of ADEPT.
Subgroup analysis of patients with and without radiographic
progression to week 24 of ADEPT
Among adalimumab-treated patients with no progression from
baseline to week 24 (non-progressors, table 2), inhibition was
Table 3 Improvements in patient-reported outcome measures during long-term adalimumab treatment
Patient-reported outcome measure
Duration of adalimumab exposure, weeks
24, N 48, N 72, N 104, N
HAQ DI*
Change from baseline, mean (SD) 20.3 (0.5) 298 20.3 (0.5) 298 20.3 (0.5) 298 20.3 (0.5) 298
Percentage change from baseline, mean (SD) 241.2 (55.7) 271 241.9 (58.5) 271 241.8 (53.1) 271 242.7 (56.1) 271
Patients{ achieving the MCID >20.3 points, % 45.6, 285 48.7, 271 47.7, 260 47.6, 231
Patients{ with complete resolution (HAQ DI = 0), % 31.9, 285 35.8, 271 38.5, 260 38.5, 231
SF-36 PCS{
Change from baseline, mean (SD) 9.0 (9.7) 284 10.2 (10.2) 285 9.7 (10.5) 286 9.4 (10.5) 286
Percentage change from baseline, mean (SD) 33.8 (41.7) 284 38.4 (44.5) 285 36.7 (45.1) 286 35.8 (44.4) 286
Patients{ achieving the MCID >3 points, % 75.0, 272 76.4, 259 74.6, 248 78.6, 42
SF-36 MCS{
Change from baseline, mean (SD) 2.5 (9.2) 284 2.4 (9.8) 285 2.3 (10.6) 286 2.3 (10.8) 286
Percentage change from baseline, mean (SD) 8.8 (26.4) 284 8.6 (27.7) 285 9.1 (29.3) 286 9.4 (30.5) 286
Patients{ achieving the MCID >3 points, % 43.8, 272 42.5, 259 45.2, 248 50.0, 42
FACIT-F1
Change from baseline, mean (SD) 6.5 (10.0) 288 6.7 (9.8) 288 6.2 (10.4) 288 6.1 (10.4) 288
Percentage change from baseline, mean (SD) 48.3 (170.6) 287 53.5 (227.3) 287 50.2 (195.4) 287 50.6 (195.7) 287
Patients{ achieving the MCID >3 points, % 66.1, 280 66.3, 267 66.5, 254 76.7, 43
DLQI"
Change from baseline, mean (SD) 26.6 (6.5) 126 26.1 (6.9) 126 25.8 (7.3) 126 25.8 (7.4) 126
Percentage change from baseline, mean (SD) 261.4 (66.9) 122 259.4 (66.7) 122 250.8 (88.6) 122 249.3 (91.6) 122
Patients{ achieving the MCID >25.7 points, % 52.9, 119 49.5, 111 48.1, 104 56.3, 16
Patients{ achieving a score of 0 or 1, % 58.8, 119 68.5, 111 57.7, 104 68.8, 16
Patient’s assessment of pain**
Change from baseline, mean (SD) 222.3 (26.8) 298 224.0 (26.9) 298 222.8 (27.2) 298 223.4 (27.6) 298
Percentage change from baseline, mean (SD) 229.4 (100.3) 296 232.4 (113.5) 296 238.9 (61.9) 296 236.0 (95.6) 296
Patients global assessment of disease activity{{
Change from baseline, mean (SD) 221.2 (27.3) 298 222.4 (28.3) 298 221.1 (28.3) 298 221.6 (28.9) 298
Percentage change from baseline, mean (SD), n 219.5 (131.4) 297 223.0 (139.9) 297 227.1 (99.5) 297 223.0 (165.2) 297
Values are by last-observation-carried-forward analysis unless otherwise noted.
*The health assessment questionnaire disability index (HAQ DI) is scored on a scale from 0 to 3 units, with a greater score indicating more functional limitations; 0 indicates
complete resolution of functional loss.
{Observed data.
{For both the short form 36 physical component summary (SF-36 PCS) and mental component summary (MCS) scores, greater values indicate improvement.
1The functional assessment of chronic illness therapy–fatigue (FACIT–F) scale score has a range from 0 to 52, with a greater score indicating less fatigue; greater values indicate
improvement.
"The dermatology life quality index (DLQI) score has a range from 0 to 30, with a greater score indicating a more impaired quality of life; lower values indicate improvement.
**Patient’s assessment of pain is based on a visual analogue scale with a range from 0 (no pain) to 100 (pain as bad as it could be).
{{Patient’s global assessment of disease activity is based on visual analogue scale range from 0 (very well) to 100 (very poorly).
MCID, minimum clinically important difference.
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change in mTSS from week 24 to 144 = 0.2). For patients who
initially received adalimumab and had progression from baseline
to week 24, the mean change in mTSS continued to increase
from weeks 24 to 144. By contrast, for patients who initially
received placebo and had progression from baseline to week 24,
progression was stabilised by adalimumab treatment, with a
mean change in mTSS of 20.1 from week 24 to week 144. For
the greater progression exhibited in the adalimumab-treated
progressor group (table 2), it is important to note that the
number of patients in this subgroup was small (n = 12), and
these patients had much more aggressive, erosive disease at
baseline (mean mTSS 74.9 (SD 96.4)) compared with the
adalimumab-treated non-progressor group (16.1 (SD 31.9);
p,0.001). There were no statistically significant differences in
any other baseline demographic or clinical characteristics
between the adalimumab-treated progressors and non-progres-
sors. Overall, this subanalysis demonstrates that the mean
changes in mTSS in the adalimumab group from week 48 to
week 144 were driven by those patients who had radiographic
progression in the first 24 weeks of adalimumab treatment.
Joint space narrowing and joint erosion components of the modified
total Sharp score
Between week 48 and week 144, for patients originally
randomly assigned to receive adalimumab in ADEPT
(N = 115), the mean change in the joint space narrowing
component of the mTSS was 0.4 (SD 1.59), and for patients
who received placebo and then switched to adalimumab
(N = 128) at week 24 of ADEPT, the mean change in the
joint space narrowing component was 0.3 (SD 1.96). Over the
same period of time, the joint erosion component of the mTSS
did not change in the adalimumab group (mean change 0.0 (SD
1.37)) and decreased slightly in patients who switched from
placebo to adalimumab (mean change 20.2 (SD 3.85)).
Joint disease
The percentages of patients achieving ACR20, ACR50 and
ACR70 in 2 years of adalimumab treatment (N = 298) are
illustrated in fig 1. The ACR20 response was achieved by 58.7%
(165/281) of patients at week 48 and 57.3% (161/281) of
patients at week 104 based on an LOCF analysis. The
percentages of patients achieving the stricter response criteria
of ACR50 and ACR70 increased over 2 years of adalimumab
treatment, from 42.7% (120/281) of patients achieving an
ACR50 response at week 48 to 45.2% (127/281) at week 104 and
from 27.8% (78/281) of patients achieving an ACR70 response
at week 48 to 29.9% (84/281) at week 104. The percentage of
patients achieving PsARC was 65.9% (195/296) at week 48 and
63.5% (188/296) at week 104. As reported,
24 at baseline in
ADEPT, 117 patients had dactylitis and 118 patients had
enthesitis. Mean improvements at week 24 in these exploratory
endpoints were greater for adalimumab patients, but the
changes were not statistically significant.
24 The dactylitis mean
change from baseline remained constant from 48 weeks of
adalimumab exposure (mean change from baseline 21.3 (SD
3.4) units) in 104 weeks of adalimumab treatment (mean
change from baseline 21.4 (SD 3.7) units). From week 48 to
week 104, the enthesitis mean change from baseline remained
constant at 20.4 (SD 1.1) units. These data indicate that joint-
related improvements that were present after 48 weeks of
adalimumab therapy were maintained throughout 2 years of
therapy.
Skin disease
Skin assessments were restricted to patients with at least 3%
body surface area involvement (N = 128) at enrollment, as
reported previously.
24 25 The percentage of patients achieving
the PASI 50, PASI 75, PASI 90, or PASI 100 response criteria
changed by 10% or less from week 48 in 2 years of adalimumab
treatment (fig 2). Notably, the percentage of patients achieving
Table 4 Summary of safety during 24-week double-blind, randomised controlled trial (ADEPT) and throughout 2 years of open-label adalimumab
exposure
AE
24-Week randomised, controlled trial
2 Years of adalimumab exposure Placebo Adalimumab
(N = 162)
n (%)
(PY 71.1)
Events
(events/100 PY)
(N = 151)
n (%)
(PY 66.8)
Events
(events/100 PY)
(N = 298)
n (%)
(PY 676.5)
Events
(events/100 PY)
Any AE 130 (80.2) 487 (684.8) 122 (80.8) 430 (644.1) 273 (91.6) 1977 (292.2)
Any AE at least possibly related to study drug 47 (29.0) 138 (194.0) 64 (42.4) 156 (233.7) 160 (53.7) 556 (82.2)
Any severe AE 11 (6.8) 13 (18.3) 5 (3.3) 5 (7.5) 54 (18.1) 71 (10.5)
Any serious AE 7 (4.3) 11 (15.5) 5 (3.3) 5 (7.5) 50 (16.8) 62 (9.2)
Any AE leading to discontinuation of study drug 5 (3.1) 6 (8.4) 6 (4.0) 6 (9.0) 20 (6.7) 22 (3.3)
Infections 64 (39.5) 109 (153.3) 68 (45.0) 88 (131.8) 207 (69.5) 521 (77.0)
Serious infections 1 (0.6) 1 (1.4) 1 (0.7) 1 (1.5) 15 (5.0) 16 (2.4)
Malignancies 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (1.3) 4 (0.6)
Lymphoma 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.1)
Non-melanoma skin cancers 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7) 2 (0.3)
Other malignancies 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.1)
Demyelinating disease 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Injection-site reaction 5 (3.1) 36 (50.6) 10 (6.6) 39 (58.4) 43 (14.4) 221 (32.7)
Opportunistic infection excluding tuberculosis* 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (1.3) 4 (0.6)
Tuberculosis (peritoneal) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.1)
Lupus and lupus-like syndrome 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Congestive heart failure 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Death{ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.0) 3 (0.4)
*All four patients had oral candidiasis.
{One death occurred outside of the adverse event (AE) reporting period that extends 70 days (equivalent to five adalimumab half-lives) beyond the last adalimumab injection.
ADEPT, Adalimumab Effectiveness in Psoriatic Arthritis Trial; PY, patient-years.
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disease) remained above 20% between weeks 48 and 104 of
adalimumab treatment. The mean percentage improvement in
PASI from baseline was sustained within a range of 5 percentage
points from week 48 (68.5 (SD 52.0)) to week 104 (63.9 (SD
58.6)). For the physician’s global assessment of psoriasis, the
percentages of patients falling into the ‘‘clear’’ or ‘‘almost clear’’
categories were 6.2% (8/129) at baseline, 63.6% (82/129) at
week 48 and 56.6% (73/129) at week 104 (LOCF analyses).
Thus, skin-related improvements that were present after
48 weeks of adalimumab therapy
25 were maintained throughout
2 years of therapy for most patients.
Health-related quality of life
Results of the HRQOL assessments at week 24 of the open-label
extension have previously been reported
26 and are included in
table 3 for reference. At week 24 of ADEPT, all HRQOL
assessments were statistically significantly improved in adali-
mumab-treated patients compared with placebo-treated
patients, with the exception of the short form 36 health survey
(SF-36) mental component summary (MCS) mean score and the
SF-36 role–emotional domain mean score.
26
The mean change from baseline in the HAQ DI remained
20.3 units from week 48 to week 104, and the observed
percentage of patients with HAQ DI of 0 increased from 35.8%
at week 48 to 38.5% at week 104 (table 3). The observed
percentage of patients achieving the minimum clinically
important difference (MCID) in HAQ DI (>20.3 point change
from baseline)
27 was 48.7% at week 48 and 47.6% at week 104.
Mean scores for the SF-36 physical component summary
(PCS) and the MCS scores remained unchanged throughout the
study (table 3). The observed percentages of patients who
achieved the MCID in the SF-36 (>3 points change from
baseline)
28 increased slightly from weeks 48 to 104 for the PCS
(76.4% to 78.6%) and for the MCS (42.5% to 50.0%).
The mean absolute functional assessment of chronic illness
therapy–fatigue (FACIT–F) score had increased (improved) by
6.7 (SD 9.8) units from baseline at week 48 and by 6.1 (SD 10.4)
units at week 104 (table 3). The observed percentage of patients
who achieved the MCID (>3 points change from baseline)
increased from 66.3% at week 48 to 76.7% at week 104.
The mean absolute change from baseline in the DLQI varied
minimally between week 48 (26.1 (SD 6.9)) and week 104
(25.8 (SD 7.4); table 3). Based on observed data, the percentage
of patients who achieved the MCID (a change of >25.7 points
in the DLQI from baseline) was 49.5% after 48 weeks and 56.3%
after 104 weeks of adalimumab treatment. At week 48, 68.5%
(76/111) of patients achieved a DLQI score of 0 or 1 and at week
104, 68.8% (11/16) of patients had a score of 0 or 1 (observed
data).
Improvements in the patients’ assessment of pain and the
patients’ global assessment of disease activity were maintained
from week 48 to week 104 (table 3).
Safety
Adalimumab was generally well tolerated throughout 2 years of
adalimumab exposure (N = 298). There were no clinically
meaningful differences between the first 48 weeks of adalimu-
mab exposure
25 and the entire 104 weeks of adalimumab
exposure. The most common adverse events in 2 years of
exposure were similar to the type of adverse events observed in
the 24-week ADEPT study
24 and in 48 weeks of adalimumab
treatment,
25 with upper respiratory tract infection occurring in
21.5% of patients (64/298), nasopharyngitis occurring in 17.4%
(52/298) and sinusitis occurring in 10.7% (32/298). Of the 298
patients in the 2-year safety population, 273 (91.6%) experi-
enced at least one adverse event (table 4). Fifty patients (16.8%)
experienced at least one serious adverse event. The most
common serious adverse event was cholelithiasis, seen in three
patients (1.0%). The following serious adverse events were each
reported in two patients (0.7%): myocardial infarction, appen-
dicitis, urinary tract infection, osteoarthritis, psoriatic arthro-
pathy, convulsion and nephrolithiasis. Twenty patients (6.7%)
discontinued study drug as a result of an adverse event;
however, no single type of adverse event was associated with
discontinuation in more than one patient. Throughout 2 years
of adalimumab exposure, 7.0% (21/298) of patients ever had an
alanine aminotransferase value three or more times the upper
limit of normal, and 4.7% (13/298) of patients ever had an
aspartate aminotransferase value three or more times the upper
limit of normal. As previously reported, most changes in
transaminase values were transient and resolved during
continued adalimumab treatment.
24 25
During the first 48 weeks of adalimumab exposure, there
were no reports of tuberculosis, demyelination, lymphoma or
carcinoma, drug-induced lupus, or congestive heart failure.
25
Throughout 2 years of adalimumab exposure, one patient had
peritoneal tuberculosis and four patients experienced opportu-
nistic infections (oral candidiasis). One patient had non-
Hodgkin’s B-cell lymphoma, two patients had basal cell
carcinoma and one patient had neuroendocrine carcinoma of
the skin. There were no reports of central nervous system
demyelinating disease, lupus-like syndrome, congestive heart
failure, or adalimumab-related allergic reactions.
Three deaths occurred among the 298 patients. One patient
experienced cardiopulmonary arrest and myocardial infarction
that were probably not related to study drug. Another patient
experienced sudden death that was attributed to acute
pulmonary oedema and was considered possibly related to
study drug. The third death was caused by myocardial
infarction 104 days after the last dose of adalimumab and was
probably not related to study drug.
DISCUSSION
ADEPT is the largest randomised controlled study to date that
investigated the use of a TNF antagonist for the treatment of
patients with PsA. The ADEPT 24-week results established that
adalimumab was more efficacious than placebo in treating
arthritis and skin disease and inhibiting radiographic progression
in PsA, and significantly improved physical function and
HRQOL while being well tolerated.
24 26 Patients completing
ADEPT could enroll in an open-label extension trial, during
which they received 40 mg adalimumab subcutaneously every
other week for up to a total of 144 weeks. Interim results from
the open-label extension study demonstrated that clinical
efficacy, inhibition of radiographic progression and a favourable
risk–benefit profile of adalimumab were maintained throughout
48 weeks of treatment.
25 The analyses reported here establish
the clinical efficacy of adalimumab for at least 2 years of
treatment and the inhibition of structural progression of PsA for
at least 2.75 years of treatment. The favourable risk–benefit
profile of adalimumab was also sustained during long-term
treatment of patients with PsA and is consistent with that of
other TNF antagonists.
29 30
The inhibition of joint damage previously demonstrated
throughout 48 weeks of adalimumab treatment
25 was sustained
for 144 weeks of treatment. Among patients originally randomly
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radiographic progression of structural disease at week 48,
84.3% continued without progression to week 144. Patients
who switched to adalimumab treatment after 24 weeks of
placebo demonstrated inhibition of radiographic progression,
as measured by a mean mTSS that was comparable in
magnitude to the inhibition of radiographic progression
measured in patients who were treated continuously with
adalimumab. In addition, placebo-treated patients who had
radiographic progression to week 24 of ADEPT had inhibition
of progression after switching to adalimumab. These results
suggest that treatment delays may contribute to the progres-
sion of structural damage in patients with PsA.
Further analysis of patients with and without radiographic
progression from baseline to week 24 of ADEPT demonstrated
that the mean increase in mTSS to week 144 for patients
originally randomly assigned to receive adalimumab was
attributable to those patients who had radiographically defined
progression of structural damage from baseline to weeks 24 and
48. This finding suggests that there may be a small subgroup of
patients who do not respond to adalimumab despite continued
treatment. Additional analyses (data not shown) indicated that
there were no clinical responses to adalimumab treatment that
correlated with radiographic progression versus non-progres-
sion. The 12 adalimumab-treated patients who had radiographic
progression during the first 24 weeks of ADEPT continued in
the open-label extension to week 144, suggesting a clinical
benefit of adalimumab despite structural disease progression.
In addition to inhibiting radiographic progression in patients
with PsA, adalimumab resulted in sustained improvement of
joint and skin-related symptoms throughout 2 years of treat-
ment. Improvements in PsARC, dactylitis and enthesitis were
maintained between week 48 and week 104. The percentage of
patients achieving ACR20 was sustained and the percentages of
patients achieving ACR50 and ACR70 increased slightly in
2 years of adalimumab treatment. Improvements in PASI that
were seen at week 48 were constant to week 104.
Approximately one in five patients achieved and sustained
PASI 100 during long-term adalimumab treatment, indicating
full clearance of skin signs of psoriasis. This magnitude of
improvement in skin disease has not been demonstrated with
the use of other TNF antagonists during long-term treatment of
PsA. Of the various clinical responses, PASI 50 was found to be a
sensitive indicator of reduced radiographic progression in
patients with PsA treated with adalimumab for 24 weeks.
31
Although the trend was still present after 2 years of adalimu-
mab treatment, the correlation between PASI 50 response and
reduced radiographic progression was no longer statistically
significant. These sustained improvements in joint and skin-
related symptoms probably contributed to HRQOL improve-
ments that were maintained throughout 2 years of adalimumab
treatment. DLQI scores of 0 to 1 indicate that skin disease has
no effect on a patient’s quality of life,
32 and DLQI scores of 0 or
1 were achieved by approximately 60% of patients during long-
term adalimumab treatment.
The safety profile of adalimumab during long-term treatment
of PsA was consistent with the safety profile during short-term
treatment. There were no clinically meaningful changes in the
type and frequency of adverse events compared with 24 or
48 weeks of adalimumab treatment.
24 25 With the exception of a
marked decrease in mean C-reactive protein concentrations (a
known marker for clinical improvement), changes in laboratory
values from weeks 48 to 104 were not clinically significant.
There was no indication of an increase in TNF-associated
adverse events, including serious infections such as tuberculosis,
or in malignancies, demyelination, congestive heart failure and
lupus-like syndrome.
The safety profile of adalimumab demonstrated throughout
2 years of exposure in patients with PsA was consistent with
that reported for more than 10 000 patients in RA clinical
trials
21–23 33 and also with the safety profile of the adalimumab
postmarketing safety database.
33
The short-term clinical benefits of adalimumab therapy in
patients with PsA are maintained over 2 years of treatment and
the ability of adalimumab to inhibit structural progression of
the disease is maintained over 2.75 years of treatment.
Compared with short-term adalimumab treatment, there were
no additional safety concerns during long-term treatment.
Overall, adalimumab presents a favourable risk–benefit profile
in patients with PsA.
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